Wedbush Weighs in on G1 Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:GTHX)

G1 Therapeutics, Inc. (NASDAQ:GTHX) – Investment analysts at Wedbush raised their Q2 2024 EPS estimates for G1 Therapeutics in a report released on Wednesday, May 1st. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.18) per share for the quarter, up from their prior estimate of ($0.20). Wedbush currently has a “Outperform” rating and a $5.00 price target on the stock. The consensus estimate for G1 Therapeutics’ current full-year earnings is ($0.59) per share. Wedbush also issued estimates for G1 Therapeutics’ Q3 2024 earnings at ($0.14) EPS, Q4 2024 earnings at ($0.14) EPS, FY2024 earnings at ($0.64) EPS, Q1 2025 earnings at ($0.13) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.49) EPS and FY2026 earnings at ($0.37) EPS.

G1 Therapeutics (NASDAQ:GTHX) last issued its quarterly earnings data on Wednesday, May 1st. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The firm had revenue of $14.48 million for the quarter, compared to analysts’ expectations of $15.21 million. G1 Therapeutics had a negative net margin of 36.40% and a negative return on equity of 74.75%. During the same quarter in the previous year, the business earned ($0.53) EPS.

GTHX has been the subject of a number of other reports. Needham & Company LLC reiterated a “buy” rating and set a $12.00 target price on shares of G1 Therapeutics in a research report on Wednesday, May 1st. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of G1 Therapeutics in a research report on Thursday, May 2nd.

G1 Therapeutics Stock Performance

NASDAQ GTHX opened at $4.25 on Monday. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.94 and a quick ratio of 2.55. G1 Therapeutics has a 1-year low of $1.08 and a 1-year high of $5.00. The business has a 50 day simple moving average of $4.02 and a two-hundred day simple moving average of $3.15. The stock has a market capitalization of $222.19 million, a PE ratio of -6.85 and a beta of 1.71.

Institutional Trading of G1 Therapeutics

A number of large investors have recently modified their holdings of GTHX. Creative Financial Designs Inc. ADV raised its stake in G1 Therapeutics by 98.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 35,280 shares of the company’s stock worth $108,000 after buying an additional 17,475 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of G1 Therapeutics by 68.3% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 204,200 shares of the company’s stock worth $294,000 after acquiring an additional 82,879 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of G1 Therapeutics during the 3rd quarter worth $189,000. abrdn plc bought a new stake in G1 Therapeutics during the fourth quarter valued at about $1,293,000. Finally, Choreo LLC purchased a new position in G1 Therapeutics in the fourth quarter valued at about $107,000. Hedge funds and other institutional investors own 24.21% of the company’s stock.

Insiders Place Their Bets

In other news, insider Rajesh Malik sold 28,600 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $4.62, for a total value of $132,132.00. Following the sale, the insider now directly owns 169,938 shares in the company, valued at $785,113.56. The sale was disclosed in a document filed with the SEC, which is available at this link. 8.23% of the stock is owned by insiders.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.